Autotelic Bio has successfully closed its Series B Bridge round with investments from Kiwoom Securities and others. This round is crucial for their upcoming IPO and ongoing drug development efforts.
Round Type
Series B
Investors
Description
Autotelic Bio closed its Series B Bridge investment round, securing support from Kiwoom Securities, a strategic investor, and major reinvestments from Vine Ventures. This funding is aimed at facilitating their initial public offering and advancing the development of ATB-101. The company has cleared critical regulatory hurdles for its Phase 1 trial in the US. Follow-up investments show strong investor confidence in Autotelic Bio's technology and growth potential.
Who else raised in Pharmaceutical and Biotechnology around the same time
Companies in the same sectors as Autotelic Bio that raised within 45 days of this round, from Fundz verified event records.
- AbCellera raised $200M (Post-IPO Equity) on August 12, 2026.
- Vaderis Therapeutics raised $152M (Series B) on August 11, 2026.
- Os Therapies raised $5M on August 10, 2026.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
- Acasti raised $10M on August 4, 2026.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
Who to call at Autotelic Bio, and when
A new round usually means Autotelic Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Autotelic Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Autotelic Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Autotelic Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Autotelic Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAutotelic Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.